EIF3H — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL24532060	0.77	2/20
SCHEMBL4698636	0.76	2/20
SCHEMBL4699183	0.74	2/20
SCHEMBL24532034	0.73	2/20
SCHEMBL4696222	0.72	2/20
SCHEMBL20439526	0.68	2/20
SCHEMBL22024572	0.67	2/20
SCHEMBL4920392	0.66	2/20
SCHEMBL21942991	0.66	2/20
SCHEMBL29728046	0.64	2/20
SCHEMBL22025041	0.63	2/20
SCHEMBL29728047	0.63	2/20
SCHEMBL22025046	0.55	2/20
SCHEMBL22024728	0.52	2/20
SCHEMBL22025470	0.52	2/20
SCHEMBL22024742	0.52	2/20
SCHEMBL22025138	0.52	2/20
SCHEMBL22024582	0.47	2/20

Clinical trials — most relevant to EIF3H by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Quantification of GADD34 Expression in RA	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED
Autophagy Bladder Cancer	nan	UNKNOWN
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients	nan	SUSPENDED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF3H binder may also engage these)

Protein	Name	Similarity
Q91WK2	—	1.000	Q91WK2 →
Q6P9U8	—	1.000	Q6P9U8 →
Q5ZLE6	—	1.000	Q5ZLE6 →
B5FY35	—	1.000	B5FY35 →
Q6AXJ2	—	1.000	Q6AXJ2 →
Q56JZ5	—	1.000	Q56JZ5 →
Q9GV27	—	1.000	Q9GV27 →
B5RI54	—	1.000	B5RI54 →
B4JAS7	—	1.000	B4JAS7 →
B3MP94	—	1.000	B3MP94 →
Q5PR67	—	1.000	Q5PR67 →
B4N116	—	0.999	B4N116 →
Q9C5Z2	—	0.999	Q9C5Z2 →
B4I1C2	—	0.999	B4I1C2 →
B4P3T9	—	0.998	B4P3T9 →
Q170C2	—	0.998	Q170C2 →
Q6P381	—	0.998	Q6P381 →
Q7PVR3	—	0.997	Q7PVR3 →
Q5PPY6	—	0.996	Q5PPY6 →
B0WDA9	—	0.996	B0WDA9 →
A7SA47	—	0.996	A7SA47 →
Q9U9Q4	—	0.995	Q9U9Q4 →
B4LTW0	—	0.994	B4LTW0 →
B4KGS4	—	0.994	B4KGS4 →
A9V3P1	—	0.993	A9V3P1 →
B5DJJ2	—	0.992	B5DJJ2 →
O01974	—	0.992	O01974 →
B4KBI4	—	0.992	B4KBI4 →
Q54C49	—	0.992	Q54C49 →
Q9VCY3	—	0.991	Q9VCY3 →